Robert Lookstein, MD, FSIR, will formally become SIR president for the 2025–2026 term during today’s Members’ Business Meeting. He is currently the IR section chief at Mount Sinai.
Can you tell us about yourself and your career?
Robert Lookstein, MD, FSIR: I began my journey in general surgery but quickly realized it wasn’t my calling. During that time, I encountered the interventional radiology team at Mount Sinai—brilliant, passionate and visionary individuals who reignited my enthusiasm for medicine. Their influence led me to explore IR, and I discovered a dynamic field where innovation meets patient impact. I was fortunate to join Mount Sinai’s radiology residency and later its fellowship, ultimately becoming chief of the section in 2012. It’s been an inspiring path of growth, leadership and purpose.
How did you become involved in SIR?
RL: I’ve been a proud SIR volunteer for nearly 20 years, contributing across multiple initiatives—from founding the LEARN meeting to serving on the Economics Council and FDA Liaison Committee. I’ve held roles as program director, council chair, and served on the Board and Executive Council. Each role deepened my commitment to advancing IR and strengthening our community.
You’ve volunteered across many areas of SIR. Is there any volunteer project you were particularly passionate about?
RL: My greatest passion lies in advocating for patients with peripheral vascular disease. I’ve focused on improving care access and educating providers to elevate outcomes. Collaborating with federal agencies has shown that our collective voice matters—we’ve begun turning the tide for patient access and quality standards. My mission is to keep patients front and center in everything we do.
You will become the SIR president as we celebrate SIR’s 50th anniversary. What would you consider the next big opportunity for IR?
RL: Two transformational opportunities lie ahead. First, we must embrace and expand longitudinal care. Unlike our origins—where IRs met patients only moments before a procedure—today’s IRs are building relationships, following patients through their journey and providing comprehensive outpatient care. I want to grow this model worldwide and showcase its power to transform lives.
Second, our specialty’s diversity is a strength. IRs today specialize in everything from oncology to pain management, vascular care to pelvic health. This clinical expertise sets us apart. As we embrace these subspecialties, we must also elevate our visibility and recognition—not just as technical experts, but as leaders in patient-centered care.
What are some of the challenges currently facing IR? How do you plan to address them during your term as president?
RL: A key challenge is defining and communicating our value. Our expertise is clear, but demonstrating it to stakeholders—whether in hospitals or outpatient labs—requires clarity and confidence. SIR is launching a deep-dive into our specialty’s value proposition, focusing on quality, financial impact, access, and satisfaction. When IRs can articulate their value, they’re empowered to lead, grow and elevate care.
As you step into this new leadership role, what message would you like to send to current and future members of SIR, as well as the broader healthcare community?
RL: IR is evolving—and we’re leading that evolution. We provide high-quality, patient-centered, longitudinal care. Our members are driven by compassion, innovation and a commitment to equity. As president, I’ll work to amplify our mission: expanding access, advancing excellence, and ensuring that every patient—regardless of background—benefits from the power of IR.
What’s a fun fact about you that members may not know?
RL: I’m a huge live music fan—especially rock. My wife and I catch 12 to 24 shows a year, and I’m currently in line for Jack White tickets as we speak. It’s our shared passion and a great way to recharge and stay inspired.
